SNAP-CAR
THE PROMISE
OF CELL THERAPY
Chimeric antigen receptor (CAR) therapy is a new treatment for cancer in which immune cells, either from the patient or from a donor, are genetically engineered to recognize cancer cells to target and destroy them. Currently approved CAR T therapies are revolutionizing the treatment of many blood cancers including B cell leukemias and lymphomas by targeting specific proteins found on these cancers, and there is hope in treating additional cancers including solid tumors by having them recognize new targets.
OUR APPROACH:
SNAP-CAR
Coeptis is developing a novel approach to immune-based cell therapy called SNAP-CAR, where the CAR is connected to tumor cells via a SNAP molecule. Instead of directly binding to a tumor cell, the CAR cells are co-administered with one or more antibody adaptors that bind to the tumor cells via a covalent bond. This type of bond is the highest affinity bond possible, thus this binding is expected to translate to highly potent therapeutic activity. The antibody adaptors can be increased (to heighten potency) or decreased (to reduce toxicity) as needed.
PROMISING PRECLINICAL DATA
Pre-clinical studies in mice have demonstrated that by targeting tumors via antibody adaptor molecules, the SNAP-CAR therapy provides a highly programmable therapeutic platform that may present several potential advantages over standard CAR T treatments. A number of different tumor targets have been successfully tested, with more testing ongoing.
SNAP-CAR IN ACTION
Animations herein are provided as visual aids to help articulate hypothesized proof-of-concept in a general manner and do not depict precise scientific mechanisms-of-action.
Proprietary Platform Technology:
A monoclonal antibody conjugated (tagged) to a benzyl guanine linker, which is recognized by the custom SNAP-CAR cells, which allows for tunable oncology or autoimmune treatment (covered by strong core IP)
Potential to generate a variety of SNAP-CAR effector cells (T cells and NK cells) in the autologous or allogeneic settings
Advantages:
Multiple targets and indications: By using universal SNAP-CAR cells and multiple anti-tumor antibodies, hematological malignancies, and solid tumors can be targeted
Tunable Activity: toxicity (ex: cytokine release syndrome) may be avoided by titrating the antibody dose
